IART vs. ITGR, ATRC, ATEC, OFIX, SRDX, ANGO, ARAY, RMTI, RSLS, and ABT
Should you be buying Integra LifeSciences stock or one of its competitors? The main competitors of Integra LifeSciences include Integer (ITGR), AtriCure (ATRC), Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "health care equipment" industry.
Integra LifeSciences vs.
Integer (NYSE:ITGR) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
99.3% of Integer shares are held by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are held by institutional investors. 2.0% of Integer shares are held by company insiders. Comparatively, 3.1% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Integra LifeSciences received 47 more outperform votes than Integer when rated by MarketBeat users. However, 63.93% of users gave Integer an outperform vote while only 56.83% of users gave Integra LifeSciences an outperform vote.
Integer presently has a consensus price target of $147.67, suggesting a potential upside of 13.63%. Integra LifeSciences has a consensus price target of $23.00, suggesting a potential upside of 8.85%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Integra LifeSciences.
In the previous week, Integer had 23 more articles in the media than Integra LifeSciences. MarketBeat recorded 27 mentions for Integer and 4 mentions for Integra LifeSciences. Integer's average media sentiment score of 0.41 beat Integra LifeSciences' score of 0.18 indicating that Integer is being referred to more favorably in the media.
Integer has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.
Integer has a net margin of 6.70% compared to Integra LifeSciences' net margin of -0.42%. Integra LifeSciences' return on equity of 12.35% beat Integer's return on equity.
Integer has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Summary
Integer beats Integra LifeSciences on 14 of the 18 factors compared between the two stocks.
Get Integra LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integra LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:IART) was last updated on 2/22/2025 by MarketBeat.com Staff
Free IART Stock Alerts